ELOXX PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.99 per share for the 12-month period ending 2025-12-31, per its S-1 filed 2026-09-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-09-11
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2018-03-31 was $4.32.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2013-09-30 was $4.23.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2011-09-30 was $0.18.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $12.20, a 80.45% decline from fiscal 2021.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $62.40, a 2624.89% increase from fiscal 2020.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $2.29, a 63.54% decline from fiscal 2019.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $6.28, a 65.23% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.99 S-1 · filed 2026-09-11 | $0.09 10-K · filed 2026-03-17 | |||
| 2023-12-31 | $34.43 S-1 · filed 2026-09-11 | $3.13 10-K · filed 2026-03-17 | |||
| 2022-12-31 | $12.20 10-K · filed 2023-03-31 | ||||
| 2021-12-31 | $62.40 10-K · filed 2023-03-31 | $1.56 10-K · filed 2022-03-30 | |||
| 2020-12-31 | $2.29 10-K · filed 2022-03-30 | ||||
| 2019-12-31 | $6.28 10-K · filed 2022-03-30 | ||||
| 2018-12-31 | $18.06 10-K · filed 2021-03-12 | ||||
| 2018-09-30 | $10.97 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | $11.59 10-Q · filed 2018-08-10 | ||||
| 2018-03-31 | $4.32 10-Q · filed 2018-05-10 | ||||
| 2017-12-31 | $3.68 10-K · filed 2020-03-06 | ||||
| 2017-06-30 | $0.22 10-K · filed 2017-10-13 | ||||
| 2016-12-31 | $0.14 10-K · filed 2019-03-14 | ||||
| 2016-06-30 | $0.31 10-K · filed 2016-10-13 | ||||
| 2015-12-31 | $0.17 10-K · filed 2018-03-16 | ||||
| 2015-06-30 | $0.49 10-K · filed 2015-10-09 | ||||
| 2015-03-31 | $0.56 10-Q · filed 2015-05-14 | ||||
| 2014-12-31 | $0.60 10-Q · filed 2015-02-17 | ||||
| 2014-06-30 | $2.11 10-K · filed 2015-10-09 | ||||
| 2014-03-31 | $4.22 10-Q · filed 2014-05-09 | ||||
| 2013-12-31 | $4.22 10-Q · filed 2014-02-14 | ||||
| 2013-09-30 | $4.23 10-Q · filed 2013-11-14 | ||||
| 2013-06-30 | $11.00 10-K · filed 2015-10-09 | $0.11 10-K · filed 2013-09-11 | |||
| 2013-03-31 | $0.12 10-Q · filed 2013-05-15 | ||||
| 2012-12-31 | $0.13 10-Q · filed 2013-02-14 | ||||
| 2012-06-30 | $17.00 10-K · filed 2014-09-29 | $0.17 10-K/A · filed 2012-10-26 | |||
| 2012-03-31 | $0.17 10-Q · filed 2013-05-15 | ||||
| 2011-12-31 | $0.17 10-Q · filed 2013-02-14 | ||||
| 2011-09-30 | $0.18 10-Q · filed 2012-11-14 | ||||
| 2011-06-30 | $0.33 10-K · filed 2013-09-11 | ||||
| 2010-06-30 | $0.45 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |